LEQEMBI (lecanemab-irmb) for Alzheimer

Hope is on the Horizon

In a groundbreaking development, the FDA has finally awarded traditional approval for the Alzheimer’s drug LEQEMBI, the first medication shown to slow down the progression of the devastating and thought-to-be-irreversible disease. 

This highly anticipated decision brings hope to millions of people in the early phase, as it could significantly expand their access to this groundbreaking therapy that has been proven to clear amyloid plaque buildup in the brain, a characteristic feature of Alzheimer’s. LEQEMBI has exhibited a 27% slowing of cognitive decline and function in an 18-month clinical trial. While it does not provide a permanent cure, this medication means a notable breakthrough in this disease’s research and treatment.

This moment marks an outstanding milestone in the fight against Alzheimer’s and a new era of hope, progress, and expanded access to a treatment that makes a difference in the lives of millions of people around the world.

At Thrivewell Infusion Center, we offer LEQEMBI IV treatment to our patients as a tool to slow down the negative and debilitating effects of Alzheimer’s. Please call us at 212-803-3339 or visit our centers in New York, New Jersey, Illinois, California, Tennessee, and Chicago for more information on this medication and its remarkable benefits.